Source comparison
Tesamorelin HIV Lipodystrophy 2026: Comparison of Treatment Options
Before presenting the comparison, understand that no single intervention addresses all components of HIV-associated lipodystrophy. VAT accumulation, subcutaneous lipoatrophy, and metabolic dysregulation often coexist and require multimodal approaches. Tesamore
This comparison does not assign a generated winner or score.
- Before presenting the comparison, understand that no single intervention addresses all components of HIV-associated lipodystrophy. VAT accumulation, subcutaneous lipoatrophy, and metabolic dysregulation often coexist and require multimodal approaches.
- Tesamorelin 2mg daily
- GHRH analog stimulating pulsatile GH release → visceral lipolysis
- 15–20% at 26 weeks (clinical trials)
- Minimal to none. Subcutaneous fat unchanged
- Modest triglyceride reduction (10–15%); small HbA1c increase (0.2–0.4%)
- VAT reaccumulates within 12–24 weeks of discontinuation
- Gold standard for VAT reduction in HIV lipodystrophy; requires continuous use; glucose monitoring essential
- Dietary intervention + exercise
- Caloric deficit → generalized fat oxidation
- 5–10% (inconsistent across patients)
- Proportional reduction in subcutaneous and visceral fat
- Improved insulin sensitivity if sustained
- Depends entirely on adherence. Typically regain within 6–12 months
- Foundation therapy but insufficient as monotherapy for ART-induced VAT; pairs well with tesamorelin
- Liposuction (surgical)
- Mechanical removal of adipose tissue
- 30–50% immediate reduction (procedure-dependent)
- Targets subcutaneous fat primarily; visceral fat not accessible
- No metabolic benefit; may worsen insulin resistance transiently
- Permanent removal of excised fat cells but no prevention of new accumulation
- Cosmetic solution for subcutaneous lipoatrophy; does not address visceral pathology or metabolic risk
- GLP-1 agonists (off-label)
- Appetite suppression + delayed gastric emptying → caloric deficit
- 8–12% total body weight reduction (includes subcutaneous and visceral)
- Significant subcutaneous fat loss
- Improved glycemic control and lipid profiles
- Weight regain typical within 6–12 months of stopping
- Not selective for VAT; useful if concurrent obesity or type 2 diabetes but not FDA-approved for lipodystrophy
- Growth hormone (exogenous)
- Direct GH replacement → lipolysis
- 10–15% VAT reduction
- Variable; can reduce subcutaneous fat but risk of lipohypertrophy at injection sites
- High risk of insulin resistance, hyperglycemia, and edema
- Rebound VAT accumulation within weeks
- Effective but side effect profile limits use; tesamorelin preferred for lower risk and physiologic GH pulsatility